Neoadjuvant imatinib: longer the better, need to modify risk stratification for adjuvant imatinib

BACKGROUND: Multimodality treatment of gastrointestinal stromal tumor (GIST) with surgery and adjuvant imatinib mesylate (IM), along with an emerging role for neoadjuvant IM prior to evaluation for resectability has resulted in high survival rates. METHODS: We conducted a retrospective analysis of p...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:J Gastrointest Oncol
Asıl Yazarlar: Ramaswamy, Anant, Jain, Deepak, Sahu, Arvind, Ghosh, Joydeep, Prasad, Priya, Deodhar, Kedar, Shetty, Nitin, Banavali, Shripad, Shrikhande, Shailesh, Ostwal, Vikas
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: AME Publishing Company 2016
Konular:
Original Article
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC4963379/
https://ncbi.nlm.nih.gov/pubmed/27563454
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.21037/jgo.2016.03.13
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller